Biocryst Pharmaceuticals Broad-Spectrum Antiviral BCX4430 Highly Effective Against Yellow Fever in a Preclinical Disease Model
Published: Nov 12, 2012
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced proof-of-principle data demonstrating that BCX4430 is efficacious and well tolerated in a preclinical disease model for evaluating efficacy against yellow fever virus infection. BCX4430 is the lead compound in BioCryst’s broad-spectrum antiviral (BSAV) research program. The objective of BioCryst’s BSAV program is to develop broad-spectrum parenteral and oral therapeutics for viruses that pose a threat to national health and security.